Scholarly article on topic 'Metallo-β-lactamase and genetic diversity of Pseudomonas aeruginosa in intensive care units in Campo Grande, MS, Brazil'

Metallo-β-lactamase and genetic diversity of Pseudomonas aeruginosa in intensive care units in Campo Grande, MS, Brazil Academic research paper on "Biological sciences"

CC BY-NC-ND
0
0
Share paper
OECD Field of science
Keywords
{" Pseudomonas aeruginosa " / "drug resistance / multiple" / beta-lactamases / electrophoresis / gel / pulsed-field}

Abstract of research paper on Biological sciences, author of scientific article — Ana Claudia Souza Rodrigues, Marilene Rodrigues Chang, Gabriela Dorn Nóbrega, Mayara Souza Rodrigues, Nadia Cristina Pereira Carvalho, et al.

Abstract Infection by Pseudomonas aeruginosa has spread worldwide, with limited options for treatment. The purpose of this study was to investigate metallo-β-lactamase-producing P. aeruginosa strains and compare their genetic profile using samples collected from patients in intensive care units. Forty P. aeruginosa strains were isolated from two public hospitals in Campo Grande, Mato Grosso do Sul State, from January 1st, 2007 to June 31st, 2008. Profiles of antimicrobial susceptibility were determined using the agar diffusion method. Metallo-β-lactamase was investigated using the double-disk diffusion test and PCR. Molecular typing was performed by pulsed-field gel electrophoresis (PFGE). Respiratory and urinary tracts were the most common isolation sites. Of the 40 samples tested, 72.5% (29/40) were resistant to ceftazidime and 92.5% (37/40) to imipenem, whereas 65% (26/40) were resistant to both antimicrobials. Fifteen pan-resistant samples were found. Five percent (2/40) of samples were positive for metallo-β-lactamase on the phenotype test. No metallo-β-lactamase subtype was detected by PCR. Macrorestriction analysis revealed 14 distinct genetic patterns. Based on the superior accuracy of PCR, it can be inferred that P. aeruginosa isolates from the investigated hospitals have alternative mechanisms of carbapenem resistance. The results also suggest clonal spread of P. aeruginosa between the studied hospitals.

Academic research paper on topic "Metallo-β-lactamase and genetic diversity of Pseudomonas aeruginosa in intensive care units in Campo Grande, MS, Brazil"

Metallo-ß-lactamase and genetic diversity of Pseudomonas aeruginosa in intensive care units in Campo Grande, MS, Brazil

ABSTRACT

Infection by Pseudomonas aeruginosa has spread worldwide, with limited options for treatment. The purpose of this study was to investigate metallo-^-lactamase-producing P aeruginosa strains and compare their genetic profile using samples collected from patients in intensive care units. Forty P aeruginosa strains were isolated from two public hospitals in Campo Grande, Mato Grosso do Sul State, from January 1st, 2007 to June 31st, 2008. Profiles of antimicrobial susceptibility were determined using the agar diffusion method. Metallo-^-lactamase was investigated using the double-disk diffusion test and PCR. Molecular typing was performed by pulsed-field gel electrophoresis (PFGE). Respiratory and urinary tracts were the most common isolation sites. Of the 40 samples tested, 72.5% (29/40) were resistant to ceftazidime and 92.5% (37/40) to imipenem, whereas 65% (26/40) were resistant to both antimicrobials. Fifteen pan-resistant samples were found. Five percent (2/40) of samples were positive for metallo-^-lactamase on the phenotype test. No metallo-^-lactamase subtype was detected by PCR. Macrorestriction analysis revealed 14 distinct genetic patterns. Based on the superior accuracy of PCR, it can be inferred that P. aeruginosa isolates from the investigated hospitals have alternative mechanisms of carbapenem resistance. The results also suggest clonal spread of P. aeruginosa between the studied hospitals.

Keywords: Pseudomonas aeruginosa; drug resistance, multiple; beta-lactamases; electrophoresis; gel; pulsed-field.

[Braz J Infect Dis 2011;15(3):195-199]©Elsevier Editora Ltda.

INTRODUCTION

Pseudomonas aeruginosa, a non-fermenting Gram-negative rod of great clinical and epidemiological relevance in hospital-acquired infections, is more frequently found in intensive care units (ICUs)1 and is associated with high mor-bimortality.2

The selective pressure exerted by the indiscriminate use of antimicrobial agents in the last decades might have contributed to the emergence of microorganisms that are resistant to different classes of antibiotics and is currently a matter of worldwide concern.3 Several mechanisms are involved in P. aeruginosa resistance to antimicrobial agents, such as chromosomal expression, ^-lactamase production, efflux pumps and decrease in membrane permeability.4

The currently observed increased resistance to carbapenem has stimulated studies aiming at a better understanding of the resistance mechanisms of P aeruginosa.356 The emergence and dissemination of metallo-^-lactamases (MBL)

have contributed to the high rate of resistance among the P. aeruginosa strains isolated in the last decades. The MBL production knowledge is crucial to implement preventive measures that can curb the expansion of bacteria presenting this potent resistance gene.3

The objective of the present study was to investigate metallo-^-lactamase and genetic similarity among P. aeruginosa strains isolated in ICUs of two hospitals in the city of Campo Grande, state of Mato Grosso do Sul, Brazil.

MATERIALS AND METHODS

Research site and period

The study was carried out with P. aeruginosa strains from patients admitted at adult ICUs, coronary care units (CCUs) and pediatric ICUs (PICUs) of two public hospitals in the state of Mato Grosso do Sul, Brazil, from 01/01/2007 to 06/31/08. Hospital A is a 250-bed university hospital and hospital B is a 360-bed tertiary hospital.

Authors

Ana Claudia Souza Rodrigues1 Marilene Rodrigues Chang2 Gabriela Dorn Nóbrega3 Mayara Souza Rodrigues3 Nadia Cristina Pereira Carvalho4 Beatriz Garcia Gomes5 Denio Lopes de Almeida6 Karyne Rangel Carvalho7 Marise Dutra Asensi8

'MD; Teacher, Health and Development Post-graduation Program, Central-West Region, Universidade Federal de Mato Grosso do Sul, MS, Brazil 2PhD; Teacher, Department of Pharmacy and Biochemistry, Universidade Federal de Mato Grosso do Sul, MS, Brazil 3Pharmacist; Postgraduate student, Department of Pharmacy and Biochemistry, Universidade Federal de Mato Grosso do Sul, MS, Brazil 4Pharmacist; Postgraduate student, Hospital Universitário, Universidade Federal de Mato Grosso do Sul, MS, Brazil

5Pharmacist; Postgraduate student, Hospital Regional de Mato Grosso do Sul, MS, Brazil

6Graduate student; Department of Pharmacy and Biochemistry, Universidade Federal de Mato Grosso do Sul, MS, Brazil 7MD; Postgraduate student, Laboratório de Pesquisa em Infec^ao Hospitalar/IO C/FIO CRUZ, RJ, Brazil 8PhD; Researcher, Laboratório de Pesquisa em Infec^ao Hospitalar/IOC/ FIOCRUZ, RJ, Brazil

Submitted on: 11/06/2010 Approved on: 12/21/2010

Correspondence to:

Ana Claudia Souza Rodrigues Rua Melanias Barbosa, 380. Bloco 3 ap.302 Taquarussu, Campo Grande MS/Brasil

Phone: 67- 33319974 / 67-84016036/ (Fax) 33227107 anaclaurod@yahoo.com.br

Financial Support: FUNDECT/ MS - Funda^ao de Apoio ao Desenvolvimento do Ensino, Ciencia e Tecnologia do Estado de Mato Grosso do Sul.

We declare no conflict of interest.

Inclusion criteria

P. aeruginosa strains resistant to ceftazidime and/or imipenem, isolated from several types of biological material were included in the study. One sample was obtained from each patient and stored in a strain bank at the hospitals. These strains were randomly selected without distinction regarding infection or colonization and were not obtained from surveillance cultures.

Bacterial identification and susceptibility to antibiotic agents

P. aeruginosa isolates were identified using conventional methodology.7 The antimicrobial susceptibility was determined by the agar diffusion method, according to the Clinical Laboratory Standard Institute (CLSI) recommendations.8 The tested antibiotics were polymyxin - POL (10 (g), tazobactam + piperacillin - TZP (100/10 (g), imipenem - IPM (10 (g), meropen-em - MER (10 (g), amikacin - AMI (30 (g), gentamicin - GEN (10 (g), aztreonam - ATM (30 (g), cefepime - CPM (30 (g), ceftazidime - CAZ (30 (g) and ciprofloxacin - CIP (5 (g). P. aeruginosa strains sensitive to polymyxin B only were considered pan-resistant.

MBL detection

MBL was detected using a phenotypic disc method as described by Arakawa et al.,9 with the modifications suggested by Picao et al.10 The samples were suspended in saline solution (0.5 in the McFarland turbidity scale) and seeded with a sterile swab on an Oxoid Mueller-Hinton Agar dish. The ceftazidime (30 (g) and imipenem (10 (g) discs were placed at a 2-cm distance from a disc without antibiotic agent, which received 5 (L of 2-mercap-topropionic acid solution diluted 1:8. After incubation at 37°C for 16 to 18 hours, samples that presented an increase in halo size around the ceftazidime or imipenem discs were considered positive. A standard strain of P. aeruginosa (SPM-1, P1088) was used as positive control, which was kindly provided by ALERTA Laboratory - UNIFESP.

P. aeruginosa strains positive for MBL production at the phenotypic test were submitted to conventional PCR.11 The starter oligonucleotides used were: blaSPM-1 F (5'CCT ACA ATC TAA CGG CGA CC3') and R (5'TCG CCG TGT CCA GGT ATA AC3'), blaIMP-1 F (5'CTA CCG CAG CAG AGT CTT TTG3') and R (5'AAC CAG TTT TGC CTT ACC AT3') blaIMP-2 F (5'GTT TTA TGT GTA TGC TTC CTT TGT AGC3') and R (5'CAG CCT GTT CCC ATG TAC G3'), blaVIM-1 F (5'GTT TGG TCG CAT ATC GCA AC3') e R (5AGA CCG CCC GGT AGA CC3'), blaVIM-2 F (5'ATG AAA GTG CGT GGA GAC3') and R (5'CTA CTC AAC GAC TGA GCG ATT TGT3').12-13

Pulsed field gel electrophoresis

Genotype determination was carried out by pulsed field gel electrophoresis (PFGE), according to Romao et al.14 Chromosomal DNA was prepared using the in situ technique in agarose blocks. A bacterial suspension at the exponential growth phase

was added to a 400 (L of BSC solution (Tris 1 M, pH 8.0, EDTA 0.5 M). After that, 5 (L of proteinase K (Sigma) and 200 (L of 1% agarose (low melting) were added to the cell suspension. The mixture was distributed in molds. The blocks were transferred to a lyse solution (TRIS 1 M, pH 8.0; EDTA 0.5 M, pH 8.0 and 10% N-lauryl sarcosine + 5 (L of proteinase K) and incubated at 50°C for 24 hours. Subsequently, the molds were washed six times with TE buffer at 37°C and incubated with enzyme buffer for one hour at 5°C. After buffer removal, the molds were incubated with restriction enzyme SpeI (Invitrogen) at 37°C for 2 hours. The electrophoresis procedure was carried out by PFGE in 1% agarose gel and run with a buffer containing 0.4X Tris Borato EDTA in the CHEF DR II system (BioRad, California). The gel run consisted in a crescent pulse time of 5 to 25s, for 18 hours at 6 V/cm at a temperature of 14°C, with an angle of 120°. The fragments were stained with ethidium bromide and photographed. The band profile was analyzed using the Gel Compar III system (Applied Maths, Belgium). The dendrogram was generated using the UPGMA algorithm.

RESULTS

A total of 40 strains of P. aeruginosa were analyzed, of which 12 were isolated from hospital A and 28 from hospital B. Of the total number of samples, 36 came from the adult intensive care unit (ICU), 3 from the coronary care unit (CCU) and 1 from the pediatric ICU. The samples were isolated from several sites: tracheal aspirate (17; 42.5%), urine (13; 32.5%), catheter tip (4; 10%), blood (2; 5%) and others (4; 10%), such as pressure ulcer secretion, sacral ulcer and trochanteric ulcer.

Table 1 shows the percentage of resistance in the presence of the tested antimicrobial agents. Of the total strains, 72.5% (29/40) were resistant to ceftazidime, 92.5% (37/40) to imipenem and 65% (26/40) had simultaneous resistance to both antimicrobials. Approximately 37.5% of the strains were considered pan-resistant. All samples were sensitive in vitro to polymyxin B.

Table 1. Antimicrobial resistance of P. aeruginosa in ICUs, Campo Grande/MS

Antimicrobial agents Resistance % (n = 40)

Cefepime 95

Imipenem 92.5

Ciprofloxacin 90

Gentamicin 85

Aztreonam 85

Amikacin 72.5

Ceftazidime 72.5

Meropenem 70

Tazobactam + piperacillin 70

Polymyxin 00

ICUs, intensive care units.

Rodrigues, Chang, Nóbrega et al.

Table 2 shows 17 different bacterial resistance patterns: six were found in hospital A and 14 in hospital B. Three resistance patterns (numbers 1, 8 and 15) were found in both hospitals studied.

The phenotypic test to detect MBL was positive in 5% (2/40) of P aeruginosa isolates; however, none of the genes in-

vestigated (bla-IMP, bla-VIM and bla-SPM) was identified by PCR. The molecular analysis generated by the PFGE disclosed 14 distinct genetic patterns (A to N). Table 2 shows some common profiles (A, B, E, F, J, K) at the two hospital institutions. Profile A was the most frequent (n = 9), of which one strain was from hospital A and eight from hospital B (Table 3).

Table 2. Phenotypic and molecular profile of P. aeruginosa. Campo Grande/MS

Profile Patterns of resistance Hosp PFGE Number of samples

01 PPT/AMI/ATM/CPM/CAZ/CIP/GEN/IPM/MER HB HA A/B/D/E A/B/J 07/1/1/1 1/2/1

02 PPT/AMI/ATM/CAZ/CIP/GEN/IPM/MER HB G 1

03 PPT/CPM/ATM/CAZ/CIP/GEN/IPM HB A 1

04 CIP/GEN/IPM HB C 1

05 AMI/CPM/CIP/GEN/IPM HB C/E 1/1

06 CPM/GEN/CIP/IPM HB C 1

07 PPT/AMI/ATM/CPM/CAZ/CIP/GEN HB C 1

08 AMI/ CPM/ ATM/ CIP/ GEN/ IPM/ MER HB HA B/C/K B 1/1/1 2

09 PPT/ ATM/CPM/CAZ/IPM HB I 1

10 PPT/ ATM/CPM/CAZ/GEN/IPM HB D 3

11 PPT/ ATM/CPM/CAZ/GEN HB M 1

12 PPT/AMI/CPM/CAZ/CIP/GEN/IPM HB J 1

13 ATM/CPM/CAZ/CIP/IPM/MER HA N 1

14 PPT/ATM/CPM/CAZ/IPM/MER HB C 1

15 PPT/AMI/ATM/CPM/CIP/GEN/IPM/MER HB HA F/H F 1/1 1

16 AMI/CPM/CAZ/CIP/GEN/IPM/MER HA L 1

17 AMI/ATM/CPM/CAZ/CIP/GEN/IPM/MER HA E/K 1/1

PFGE, pulsed field gel electrophoresis; AMI, amikacin; ATM, aztreonam; CAZ, ceftazidime; CIP, ciprofloxacin: CPM, cefepime; GEN, gentamicin; IPM, imipenem; MER, meropenem; PPT, piperacillin + tazobactam; POL, polymyxin; Hosp, hospital; HA, hospital A; HB, hospital B.

Table 3. Period and hospital where P. aeruginosa was isolated with PFGE profile A

Register Hospital Date Clinic Underlying disease Material

1777 HB 09/01/06 Adult ICU Kidney disease U

1694 HB 21/02/06 Adult ICU Neurological disease TA

1695 HB 07/03/06 Adult ICU Neurological disease TA

1696 HB 17/04/06 Adult ICU Diabetes meHitus U

1770 HA 26/6/06 Adult ICU Heart disease U

1701 HB 11/07/06 CCU Respiratory disease TA

1712 HB 27/11/06 Adult ICU Liver disease BL

1718 HB 23/03/07 Adult ICU AIDS CT

1726 HB 08/11/07 Adult ICU Respiratory disease TA

PFGE, pulsed field gel electrophoresis; ICU, intensive care unit; CCU, coronary care unit; AIDS, acquired immune deficiency syndrome; U, urine; TA, tracheal aspirate; BL, blood ; CT, catheter tip; HA, hospital A; HB, hospital B.

DISCUSSION

Patients with preexisting comorbidities, long hospital stay and those submitted to invasive procedures such as catheters and mechanical ventilation make the ICUs propitious places for P. aeruginosa dissemination,15,16 very often associated with high levels of morbimortality.17

P. aeruginosa was isolated mainly from materials such as tracheal aspirate and urine, corroborating the literature data reporting that this agent is more often isolated from the lower respiratory and urinary tracts.18-20

Resistance to different classes of antibiotics has been attributed to the combination of multiple mechanisms,4 which might explain the diversity of resistance patterns shown in Table 2.

The use of the lipopeptide class, such as polymyxin B and colistin, was abandoned for a while due to the high toxicity, but recently, it has once again become an important therapeutic option for multiresistant microorganism infections.21 Supporting this concept at the present investigation, all P. aeruginosa strains were sensitive to this drug.

The analysis of the susceptibility profile in vitro demonstrated higher levels of resistance in the presence of cefepime, imipenem and ciprofloxacin, drugs used in the treatment of severe Pseudomonas infections. On the other hand, as shown in Table 1, tazobactam in combination with piperacillin, meropenem and ceftazidime were the drugs that demonstrated the lowest resistance, suggesting that these drugs, as well as polymyxin, can be used as therapeutic option for P. aeruginosa infection in both institutions. The higher resistance of cefepime when compared to ceftazidime might indicate the presence of OXA-31, an oxacillinase that has cefepime as its preferential substrate.22

The dissemination capacity of MBL that hydrolyses expanded-spectrum ^-lactams, including cephalosporins and carbapenems, has been a matter of great concern in the world. Studies in several parts of the world have demonstrated varied rates of MBL production by P .aeruginosa, such as 6.2% in Korea,6 35% in Canada,5 and 62% in Greece.23 In Brazil, the SPM subtype has been described as the most prevalent in several regions of the country. National data have reported different rates of MBL production, which vary according to the institution and the studied region. As an example, one could cite rates of 10.9% in hospitals in Rio Grande do Sul,24 20% in Rio de Janeiro - RJ,25 and 41.9% in the state of Goias.26 Figueiredo-Mendes et al.27 described higher rates of this enzyme production (77.8%) among P. aeruginosa strains previously resistant to carbapenems in hospitals in Sao Paulo and Brasilia.

Different from what is observed in other Brazilian regions, our series did not show the presence of MBL-produc-ing P. aeruginosa. Further studies with larger sample sizes are necessary to detect the emergence of this important resistance gene in hospitals in the state of Mato Grosso do Sul.

The fact that the genes bla-SPM, bla-IMP and bla-VIM were not detected even in samples with a positive phenotypic test for MBL suggests the unreliability of the phenotypic test that was applied.

The finding of identical genetic profiles generated by PFGE in the two hospitals suggests an inter-hospital dissemination of P. aeruginosa. The high rate of healthcare professional and patient turnover between the hospitals and hospital wards might have contributed to these results.

The distribution of P. aeruginosa with A profile (Table 3) suggests inter-hospital transmission, as it was initially found in the adult ICU and it was subsequently found at the CCU of hospital B. This clone (A profile) was also isolated at different periods, which might indicate that it is endemic in this hospital. It is noteworthy the fact that many strains with this profile were sensitive only to polymyxin B, which shows high resistance of strains with this genetic pattern.

CONCLUSION

The results suggest that the resistance of P. aeruginosa to carbapenem agents in the present study is due to resistance mechanisms other than MBL production. The inter-hospital and intra-hospital clonal dissemination is a matter of concern and must be contained through preventive hospital infection control measures. Considering the emergent characteristic of MBL, its surveillance becomes important to control the transmission of this resistance mechanism.

ACKNOWLEDGEMENTS

To Debora Olartechea de Alencar, Silvana Ulisseia Kamis, Fernando Aguilar, Ligiane Stabullo, Francielle G. Bortoly Carvalho, Elaine C. M. Totino and the staff of the Departments of Microbiology of Hospital Regional de Mato Grosso do Sul and Hospital Universitario de Mato Grosso do Sul. We especially thank Dr. Ana Gales (Laboratory ALERTA/ UNIFESP) and her team for sharing their expertise in the subject and Ana Paula D'Alincourt C. Assef, from the Hospital Infection Research Laboratory of IOC/FIOCRUZ for her support with molecular biology techniques.

Part of the present study was supported by Funda^ao de Apoio ao Desenvolvimento do Ensino, Ciencia e Tecnologia of the State of Mato Grosso do Sul - FUNDECT/MS.

REFERENCES

1. Agodi A, Barchitta M, Cipresso R, Giaquinta L, Romeo MA, Denaro C. Pseudomonas aeruginosa carriage, colonization, and infection in ICU patients. Intensive Care Med 2007; 33(7):1155-61.

2. Zavascki AP, Barth AL, Goncalves AL et al. The influence of

metallo-beta-lactamase production on mortality in nosoco-

mial Pseudomonas aeruginosa infections. J Antimicrob Chem-

other 2006; 58(2):387-92.

Rodrigues, Chang, Nöbrega et al.

3. Gales AC, Menezes LC, Silbert S, Sader HS. Dissemination in distinct Brazilian regions of an epidemic carbapenem-resistant Pseudomonas aeruginosa producing SPM metallo-beta-lacta-mase. J Antimicrob Chemother 2003; 52(4):699-702.

4. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 2002; 34(5):634-40.

5. Pitout JD, Chow BL, Gregson DB, Laupland KB, Elsayed S, Church DL. Molecular epidemiology of metallo-beta-lac-tamase-producing Pseudomonas aeruginosa in the Calgary Health Region: emergence of VIM-2-producing isolates. J Clin Microbiol 2007; 45(2):294-8.

6. Yong D, Choi YS, Roh KH et al. Increasing prevalence and diversity of metallo-beta-lactamases in Pseudomonas spp., Aci-netobacter spp., and Enterobacteriaceae from Korea. Antimicrob Agents Chemother 2006; 50(5):1884-6.

7. Gilardi GL. Practical schema for the identification of nonfer-mentative gram negative bacteria encountered in medical bacteriology. Am J Med Technol 1972; 38(3):65-72.

8. CLSI. Clinical Laboratory Standard of Institute. Performance standards for antimicrobial susceptibility testing 2007; M100-S17.

9. Arakawa Y, Shibata N, Shibayama K et al. Convenient test for screening metallo-beta-lactamase-producing gram-negative bacteria by using thiol compounds. J Clin Microbiol 2000; 38(1):40-3.

10. Picao RC, Andrade SS, Nicoletti AG et al. Metallo-beta-lacta-mase detection: comparative evaluation of double-disk synergy versus combined disk tests for IMP-, GIM-, SIM-, SPM-, or VIM-producing isolates. J Clin Microbiol 2008; 46(6):2028-37.

11. Mullis K, Faloona F, Scharf S, Saiki R, Horn G, Erlich H. Specific enzymatic amplification of DNA in vitro: the polymerase chain reaction. Cold Spring Harb Symp Quant Biol 1986; 51 Pt 1:263-73.

12. Kimura S, Alba J, Shiroto K et al. Clonal diversity of metallo-beta-lactamase-possessing Pseudomonas aeruginosa in geographically diverse regions of Japan. J Clin Microbiol 2005; 43(1):458-61.

13. Jeong SH, Bae IK, Park KO et al. Outbreaks of imipenem-re-sistant Acinetobacter baumannii producing carbapenemases in Korea. J Microbiol 2006;44(4):423-31.

14. Romao CM, Faria YN, Pereira LR, Asensi MD. Susceptibility of clinical isolates of multiresistant Pseudomonas aeruginosa to a hospital disinfectant and molecular typing. Mem Inst Oswal-do Cruz 2005; 100(5):541-8.

15. Chang MR, Carvalho NC, Oliveira AL, Moncada PM, Moraes BA, Asensi MD. Surveillance of pediatric infections in a teaching hospital in Mato Grosso do Sul, Brazil. Braz J Infect Dis. 2003; 7(2):149-60.

16. Lodise TP, Miller CD, Graves J et al. Clinical prediction tool to identify patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk for multidrug resistance. Anti-microb Agents Chemother 2007; 51(2):417-22.

17. Zavascki AP, Barth AL, Fernandes JF, Moro AL, Goncalves AL, Goldani LZ. Reappraisal of Pseudomonas aeruginosa hospital-acquired pneumonia mortality in the era of metallo-beta-lac-tamase-mediated multidrug resistance: a prospective observational study. Crit Care 2006; 10(4):R114.

18. Sader HS, Gales AC, Pfaller MA et al. Pathogen frequency and resistance patterns in Brazilian hospitals: summary of results from three years of the SENTRY Antimicrobial Surveillance Program. Braz J Infect Dis 2001; 5(4):200-14.

19. Furtado GH, Martins ST, Machado AM, Wey SB, Medeiros EA. Clinical culture surveillance of carbapenem-resistant Pseudomonas aeruginosa and Acinetobacter species in a teaching hospital in Sao Paulo, Brazil: a 7-year study. Infect Control Hosp Epidemiol 2006; 27(11):1270-3.

20. Raja NS, Singh NN. Antimicrobial susceptibility pattern of clinical isolates of Pseudomonas aeruginosa in a tertiary care hospital. J Microbiol Immunol Infect 2007; 40(1):45-9.

21. Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and colis-tin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother 1999; 33(9):960-7.

22. Aubert D, Poirel L, Chevalier J, Leotard S, Pages JM, Nordmann P. Oxacillinase-mediated resistance to cefepime and susceptibility to ceftazidime in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2001; 45(6):1615-20.

23. Giakkoupi P, Petrikkos G, Tzouvelekis LS, Tsonas S, Legakis NJ, Vatopoulos AC. Spread of integron-associated VIM-type metallo-beta-lactamase genes among imipenem-nonsuscepti-ble Pseudomonas aeruginosa strains in Greek hospitals. J Clin Microbiol 2003; 41(2):822-5.

24. Graf T, Fuentefria DB, Corcao G. [Occurrence of multiresistant strains of Pseudomonas aeruginosa producing metallo-beta-lactamase blaSPM-1 in clinical samples]. Rev Soc Bras Med Trop 2008; 41(3):306-8.

25. Carvalho AP, Albano RM, de Oliveira DN, Cidade DA, Teix-eira LM, Marques Ede A. Characterization of an epidemic car-bapenem-resistant Pseudomonas aeruginosa producing SPM-1 metallo-beta-lactamase in a hospital located in Rio de Janeiro, Brazil. Microb Drug Resist 2006; 12(2):103-8.

26. Goncalves DC, Lima AB, Leao LS, Filho JR, Pimenta FC, Vieira JD. [Detection of metallo-beta-lactamase in Pseudomonas aeruginosa isolated from hospitalized patients in Goiania, State of Goias]. Rev Soc Bras Med Trop. 2009; 42(4):411-4.

27. Figueiredo-Mendes CM, Sinto S, Mello-Sampaio JL et al. Pseudomonas aeruginosa clonal dissemination in Brazilian intensive care units. Enferm Infecc Microbiol Clin. 2005; 23(7):402-5.